Hi Kelsee, I guess I should back up a bit here regarding clinical trials in the E.U. I said in my last post that I think that a number of people here are equating the trial confirmation in the press release with confirmation from the EMA. The EMA does not give such confirmation, each member state gives confirmation for trials occurring in their respective country. The EMA monitors trials and is the body that gives marketing authorization for drugs in the EEA and as such companies hoping to obtain authorization for their drugs must conduct trials which will meet the criterion set out by EEA, where ever the actual trial is held.

The way I read the press release is that RVX has one of a number of such confirmations that it will need to conduct the trial. My main point, however, was that it would be better to say nothing until you can at least say something concrete that investors can independantly verify. Especially since, IMO, none of this means anything until RVX can say with 100% certainty precisely when and where first dosing will be taking place. Hopefully when that occurs it includes FDA approval if not US sites. Right now with respect to RVX I don't think the market will have any favourable reaction to anymore half told stories. The sad thing to me is that a few months ago I thought RVX was in a great position to have a steady stream of positive news to build on the previous positive findings for RVX-208. Now they've managed to miss a self imposed deadline with respect to an ODD and they couldn't tell us where the first trial confirmation came from, once again confirming that the one thing RVX is consistantly good at is screwing up their message. All JMO